Clinical Significance of Lipoprotein and Ceruloplasmin Variations in Type 2 Diabetes Mellitus: A Cross-Sectional Study in Owo, Nigeria
Adedeji David Atere, Oluomachi Precious Nwimo, Mega Obukohwo Oyovwi, Yekeen Adebisi Kosamat, Adekunle Abiodun Adesiyan · 2026
Read Clinical Significance of Lipoprotein and Ceruloplasmin Variations in Type 2 Diabetes Mellitus: A Cross-Sectional Study in Owo, Nigeria by Adedeji David Atere, Oluomachi Precious Nwimo, Mega Obukohwo Oyovwi, Yekeen Adebisi Kosamat, Adekunle Abiodun Adesiyan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13542661.txt.
Description
Atere and colleagues compared blood markers in 2026 between fifty patients with type 2 diabetes and thirty matched controls at a federal medical center in Owo, Nigeria. They centered on ceruloplasmin, the blood's main copper-carrying protein and a suspected marker of metabolic dysfunction. The team measured blood sugar, the full lipid panel, ceruloplasmin, a damage marker called malondialdehyde, and total antioxidant status with standard assays.
The diabetes group differed significantly on sugar, ceruloplasmin, most lipid measures, and the damage marker, while total antioxidant status fell markedly, a pattern of stronger oxidative stress with weaker defense. Obese participants showed the worst lipid and stress profiles. Ceruloplasmin rose alongside the lipid measures, while the damage marker moved against antioxidant status. The authors propose ceruloplasmin as an early flag for the biochemical slide toward diabetes complications, worth adding to monitoring in similar clinics.
Catalog record
| CREATOR | Adedeji David Atere, Oluomachi Precious Nwimo, Mega Obukohwo Oyovwi, Yekeen Adebisi Kosamat, Adekunle Abiodun Adesiyan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |